Danish biopharmaceutical company H. Lundbeck A/S plans to relocate its U.S. headquarters from Deerfield, IL to the Greater Boston region while establishing a new innovation hub there. The company, which focuses on treatments for brain health and brain diseases, said the transition will take place over the next year as it reshapes its U.S. footprint around a larger presence in the Boston life sciences ecosystem.
Lundbeck identified Greater Boston as the location for a new innovation hub intended to serve as a focal point for its research, development, and collaboration activities in the United States. The hub is meant to connect Lundbeck’s internal expertise with the broader innovation ecosystem in the region, including external partners and research networks. According to the company, the move is designed to support closer collaboration across its organization as it advances its portfolio and pipeline.
The U.S. has been described by Lundbeck’s leadership as a key driver of the firm’s commercial progress and a central component of its growth ambitions. Charl van Zyl, president and CEO of Lundbeck, said the relocation and hub investment align with the next phase of the company’s Focused Innovator strategy, which emphasizes scaling opportunities in innovation and the use of AI. The decision to concentrate more activity in Greater Boston reflects the company’s view that the region can support its efforts to bring new treatments to people living with brain diseases.
The new hub will build on Lundbeck’s existing presence in Cambridge, MA, where the company is already active. By expanding around that base, Lundbeck aims to deepen its integration into the local biopharmaceutical and innovation community. The company indicated that the hub is intended to strengthen ties between its internal teams and external collaborators, though it has not yet disclosed specific real estate details.
Information about the exact location of the new headquarters and innovation hub, the type of facility involved, and the amount of space to be occupied has not been released. Lundbeck said those details, including square footage, will be reported as they become available. For now, the firm has only outlined the broad timing of the shift, indicating that the transition from Deerfield to Greater Boston will unfold over the coming year.
The relocation underscores Lundbeck’s commitment to the U.S. market and signals an operational realignment toward a region where it already has an established foothold. Market participants will be watching for follow-up announcements that clarify the scale of the planned facility and the nature of the space the company ultimately selects in the Greater Boston area.
